Cardiff Oncology (NASDAQ:CRDF) Rating Reiterated by HC Wainwright

Cardiff Oncology (NASDAQ:CRDF - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $14.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 304.62% from the stock's current price.

Separately, Piper Sandler raised their target price on shares of Cardiff Oncology from $5.00 to $7.00 and gave the stock an "overweight" rating in a report on Friday, March 1st.

Cardiff Oncology Stock Performance

Shares of CRDF stock traded down $0.06 during mid-day trading on Monday, hitting $3.46. The company's stock had a trading volume of 1,713,965 shares, compared to its average volume of 1,444,750. Cardiff Oncology has a 52-week low of $0.94 and a 52-week high of $6.42. The stock has a market cap of $154.73 million, a price-to-earnings ratio of -3.84 and a beta of 2.02. The business has a 50-day moving average price of $4.60 and a 200 day moving average price of $2.53.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.08 million. Cardiff Oncology had a negative return on equity of 54.54% and a negative net margin of 6,594.92%. Equities research analysts predict that Cardiff Oncology will post -0.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Callan Capital LLC lifted its stake in shares of Cardiff Oncology by 129.2% in the 3rd quarter. Callan Capital LLC now owns 31,147 shares of the company's stock worth $43,000 after purchasing an additional 17,560 shares during the period. PFG Investments LLC purchased a new stake in Cardiff Oncology during the first quarter valued at approximately $53,000. Finally, Assenagon Asset Management S.A. bought a new position in Cardiff Oncology in the first quarter worth approximately $1,351,000. 16.29% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.